First reported by Twitter / X
CU Anschutz Clinical Trial Tests Orforglipron, an Oral GLP-1 Pill as Alternative to Injectable Weight-Loss Drugs
New weight loss pill beats oral Ozempic in major trial
20h agoen
From the article
A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements than the leading oral semaglutide in a major clinical trial. The tablet could offer a more convenient alternative to injectable drugs like Ozempic and Wegovy because it doesn't require refrigeration or special timing with meals. It's also cheaper to manufacture, which could expand access globally.
Continue reading on ScienceDailyYou might also wanna read
CU Anschutz Clinical Trial Tests Orforglipron, an Oral GLP-1 Pill as Alternative to Injectable Weight-Loss Drugs
Orforglipron is an FDA-approved non-peptide oral GLP-1 pill being studied as an alternative to injectable weight-loss drugs like Ozempic and
news.cuanschutz.edu·1d ago
FDA Approves Foundayo (orforglipron): The First Oral GLP-1 Weight Loss Pill Without Fasting Requirements
The FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill by Eli Lilly, on April 1, 2026. Unlike other oral GLP
medicaldaily.com·6h ago
Wegovy weight-loss pill goes on sale on UK high street and online pharmacies
The Guardian·2d ago
Wegovy weight-loss pill goes on sale on UK high street and online pharmacies
The Guardian·2d ago
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·6mo ago
Daily weight loss pill available in UK pharmacies from today
The Independent·2d ago
Study Finds Ozempic Does Not Slow Alzheimer's Disease Progression
Novo Nordisk announced that its popular weight-loss drug Ozempic does not slow the progression of Alzheimer's disease, based on results from
semafor.com·7mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.